LYNOZYFIC
Launchlinvoseltamab-gcpt
BLAINJECTIONSOLUTIONPriority Review
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
LYNOZYFIC (linvoseltamab-gcpt) is linvoseltamab-gcpt is a bispecific t-cell engaging antibody that binds to the cd3 receptor expressed on the surface of t-cells and b-cell maturation antigen (bcma) expressed on the surface of multiple myeloma cells and some healthy b-lineage cells. First approved in 2025.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYNOZYFIC (linvoseltamab-gcpt) is a bispecific T-cell engaging antibody approved July 2, 2025, for multiple myeloma treatment. It binds CD3 on T-cells and BCMA on myeloma cells, activating T-cells to lyse tumor cells and release proinflammatory cytokines. This represents a novel mechanism in the crowded MM space, moving beyond immunomodulators and proteasome inhibitors.
Launch
Early-stage launch product with modest competitive pressure (30/100) presents growth opportunity for commercial teams building market presence in a saturated indication.
Mechanism of Action
Linvoseltamab-gcpt is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro, linvoseltamab-gcpt activated T-cells,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LYNOZYFIC launch presents entry/mid-career opportunity in oncology with a differentiated mechanism in a mature indication; however, limited current job market activity (0 linked positions) reflects early commercialization phase and modest competitive pressure. Roles will focus on clinical adoption, payer negotiations, and educating oncologists on bispecific T-cell engager benefits and CRS management.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.